Thank you for registering your account
Thanks for joining touchNEUROLOGY to hear about news and updates from across the Neurology community.
We’ve sent you an email to verify your email address. Please click on the link to confirm your account.
You can review your email preferences at any time or update your account details
Can we reach our goals for seizure management in drug-resistant focal epilepsy?
Watch leading experts discuss aspects of the diagnosis and treatment of drug-resistant epilepsy, including up-to-date clinical data.
- Recognize the impact of recurrent seizures in patients with drug-resistant epilepsy
- Outline the challenges associated with current standard of care approaches in the management of patients with drug-resistant epilepsy
- Assess how emerging anti-epileptic drugs might address the unmet treatment needs in patients with drug-resistant focal epilepsy
Looking back over 2018: What have we learnt about optimizing the treatment of advanced Parkinson’s disease?
Watch a series of internationally renowned clinical specialists from Europe discuss pivotal data for Parkinson’s disease from key neurology congresses throughout 2018 and consider how these findings may affect clinical practice. The potential implications of these data for optimizing outcomes for patients with advanced Parkinson’s disease are explored from both global and regional perspectives.
- Summarize the latest clinical data for emerging treatment options and treatment delivery systems for the management of motor and non-motor symptoms of Parkinson’s disease.
- Discuss the use of biomarkers for the early identification of Parkinson’s disease, and to facilitate the use of neuroprotective agents.
- Describe the use of emerging targeted agents and therapeutic strategies to manage treatment side effects and maintain patient quality of life.
Lawrence Steinman EAN, 2021: Results from the Phase 3 ULTIMATE I and II Trials
It was a pleasure to meet with Lawrence Steinman (Zimmermann Professor of Neurology & Neurological Sciences, and Pediatrics, Beckman Center for Molecular Medicine, Stanford University, Stanford, CA, USA), to discuss the results from the Phase 3 ULTIMATE I and II trials, investigating ublituximab versus teriflunomide in relapsing multiple sclerosis. The abstract entitled: ‘Ublituximab versus teriflunomide […]
Renato Mantegazza, EAN 2021: Phase 3 ADAPT Study Results
touchNEUROLOGY met with Renato Mantegazza (Department of Neuroimmunology and Neuromuscular Diseases, Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta, Milan, Italy), to discuss the phase 3 ADAPT study results investigating efgartigimod for the treatment of myasthenia gravis. The abstract entitled: ‘Safety and Tolerability of Efgartigimod in Patients with Generalized Myasthenia Gravis: Phase 3 ADAPT Study Results’ was […]
Patrick Vermersch, EAN 2021: Tolebrutinib in Patients with Progressive Multiple Sclerosis: Phase 3 PERSEUS and HERCULES Trials
It was a pleasure to meet with Patrick Vermersch (University of Lille, Lille, France) to discuss the use of tolebrutinib in patients with progressive multiple sclerosis. The abstract entitled: ‘BTK Inhibitor Tolebrutinib in Patients With Progressive MS: Design of Phase 3 PERSEUS and HERCULES Trials’ was presented at the 7th Congress of the European Academy […]
Jeffrey Cummings, AAIC 2021: Aducanumab for the Treatment of Early Alzheimer’s Disease
touchNEUROLOGY joins Jeffrey Cummings (University of Nevada, Las Vegas, NV, USA) at AAIC 2021 to discuss the EMERGE clinical trial findings and what this means for the use of aducanumab on the treatment of patients with Alzheimer’s disease. The abstract entitled “Item-level analysis of clinical measures in patients with early symptomatic Alzheimer’s disease following treatment […]
The Italian Chapter of the MOST Project: Specific Changes in the Organization of Headache Centres Can Help Improve the Patient Journey
touchREVIEWS in Neurology. 2021;17(1):48-52 DOI: https://doi.org/10.17925/USN.2021.17.1.48
In 2018, the Global Burden of Disease study placed headache disorders as the second leading cause of years lived with disability.1 As another indicator of its burden, headache was ranked among the leading causes of years lived with disability.1 Given its prevalence and severe symptom burden, headache has a consequential negative impact on the quality of life […]
Opicapone: From Preclinical Data to Real-world Evidence
touchREVIEWS in Neurology. 2021;17(1):32-5 DOI: https://doi.org/10.17925/USN.2021.17.1.32
Parkinson’s disease is now considered to be a spreading disease caused by the aggregation of abnormal alpha-synuclein.1 According to Braak et al., in stage I of the disease, alpha-synuclein pathology is found in the olfactory bulb and the dorsal nucleus of the vagus nerve,2 as well as in the enteric nervous system (Auerbach’s and Meissner’s plexuses).3 These observations […]
Regional Techniques and Interventions for Intractable Neuropathic Pain
touchREVIEWS in Neurology. 2021;17(1):16-22 DOI: https://doi.org/10.17925/USN.2021.17.1.16
Neuropathic pain arises from injury to or disease in the somatosensory nervous system.1 Normal sensation and pain sensation are both impaired and patients may present with peculiar painful characteristics such as allodynia and hyperalgesia.2 Central neuropathic pain includes pain from spinal cord injury and demyelinating diseases of the spinal cord, such as multiple sclerosis.1 Lesions or disease of […]
Development, Efficacy and Safety of Once-daily, Bedtime, Extended-release Amantadine (Gocovri®) to Treat Dyskinesia and OFF Time in Parkinson’s Disease
touchREVIEWS in Neurology. 2021;17(1):36-47 DOI: https://doi.org/10.17925/USN.2021.17.1.36
Parkinson’s disease is a progressive synucleinopathy that causes widespread neurodegeneration.1 It is estimated to affect approximately 6.1 million people globally and 0.7–1.0 million people in the USA.2–4 The incidence of the disease is expected to continue to increase over time, and with it, the burden to healthcare systems.3,4 The cardinal motor symptoms, which reflect nigral dopaminergic degeneration, are bradykinesia, […]